Navigation Links
Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
Date:11/13/2008

EAST BRUNSWICK, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Christopher Clement, President and Chief Executive Officer of Savient Pharmaceuticals will present a corporate update at the upcoming Lazard Capital Markets 5th Annual Healthcare Conference.

The presentation is scheduled to begin on Tuesday, November 18, 2008 at 9:25 a.m. ET. The Conference will be held at the St. Regis Hotel in New York City November 18-19, 2008.

Individuals can listen to a live webcast of the presentation by logging on to the Investor Relations section of Savient Pharmaceuticals' web site, http://www.savient.com. A replay of the webcast will be available on the company's web site for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, pegloticase for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and the Phase 3 clinical studies were completed in October 2007 and the BLA was filed with the FDA in October 2008. Savient has exclusively licensed worldwide rights to the technology related to pegloticase, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further information on Savient can be accessed by visiting: http://www.savient.com.

SVNT-G

Contact:

Mary Coleman

Director, Investor Relations

Savient Pharmaceuticals, Inc.

information@savient.com

(732) 418-9300


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
2. Savient Submits Biologics License Application (BLA) for pegloticase
3. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
4. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
5. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
6. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
7. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
10. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
11. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Diego, CA (PRWEB) , ... May 23, 2017 , ... ... matrix of polymeric molecules, can cause diverse pathologies ranging from food poisoning and catheter ... impact of biofilms is in the tens of billions of dollars per year, there ...
(Date:5/22/2017)... ... May 22, 2017 , ... Stratevi, a boutique firm that partners with healthcare ... has opened an office in downtown Boston at 745 Atlantic Ave. , “We ... to generate evidence on the value they provide, not just to patients, but also ...
(Date:5/21/2017)... ... May 19, 2017 , ... ... educational conference of the American Association of Bioanalysts (AAB) and the College of ... Houston. The conference reinforces AAB’s commitment to excellence in clinical laboratory services and ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... Academic researchers with technologies ripe for commercialization, and who are affiliated with ... are encouraged to submit proposals. QED, now in its tenth round, is the ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
Breaking Biology News(10 mins):